Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00206154 · ClinicalTrials.gov registry record · Phase 3
A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,500
- Enrollment target
NCT00206154 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 1,500 participants.
The verdict
NCT00206154, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,500 participants
- Enrollment target
Study Summary
The purpose of this study is to compare a combination asthma drug (Symbicort) with its two components, budesonide and formoterol, taken individually or in combination, and with placebo in the long-term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD)
Interventions
- DRUG Formoterol Turbuhaler
- DRUG Budesonide/formoterol pMDI
- DRUG Budesonide pMDI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2005-04 |
| Est. Completion | 2006-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00206154
The ClinicalTrials.gov registry entry for NCT00206154 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Formoterol Turbuhaler is the first listed.
NCT00206154 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00206154 about?
NCT00206154 is a clinical study titled "A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients". The purpose of this study is to compare a combination asthma drug (Symbicort) with its two components, budesonide and formoterol, taken individually or in combination, and with placebo in the long-term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD)
What is the current status of trial NCT00206154?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,500 participants. The study started on 2005-04. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00206154?
The interventions under investigation include: Formoterol Turbuhaler (DRUG), Budesonide/formoterol pMDI (DRUG), Budesonide pMDI (DRUG).
Who is sponsoring clinical trial NCT00206154?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.